1Hospital for Sick Children, Toronto, ON, Canada
2Nottingham Children's Hospital, Nottingham, United Kingdom
Dr. Licht reports serving on the scientific advisory boards of Alexion Pharmaceuticals and the Alport Syndrome Treatment and Outcomes Registry study and on the data and safety monitoring board of the EARLY PRO-TECT Alport study (Early Prospective Therapy Trial to Delay Renal Failure in Children with Alport Syndrome; Clinical Trials.gov number, NCT01485978). This information should have appeared on his original disclosure form. An updated disclosure form is available with the full text of the original letter at NEJM.org. Since publication of their letter, Drs. Lunn and Radhakrishnan report no further potential conflict of interest.
